Articles related to ANTITHROMBOTIC THERAPY

Pediatric pharmacists recorded 1,130 antithrombotic-related interventions involving 26.4% of 2,264 critically ill children across 9 U.S. children’s hospitals during 697 shifts from July 2023 to November 2024, with 74.7% of those interventions occurring in the pediatric cardiac ICU and 90.4% of initiation and management interventions involving anticoagulant agents.

The FDA accepted asundexian’s secondary-stroke-prevention application for Priority Review, supported by phase 3 OCEANIC-STROKE results in noncardioembolic ischemic stroke.

First-line pulsed field catheter ablation outperformed antiarrhythmic drug therapy for rhythm control at one year in patients with persistent atrial fibrillation, with similar serious adverse event rates.

“The idea of preserving and reducing thrombosis without increasing bleeding is very, very exciting.” — Roxana Mehran, MD, SCAI 2025

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.